6LP Stock Overview
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bolt Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$1.77 |
| 52 Week Low | US$0.77 |
| Beta | 1.05 |
| 1 Month Change | -11.76% |
| 3 Month Change | 5.37% |
| 1 Year Change | -31.08% |
| 3 Year Change | -93.15% |
| 5 Year Change | n/a |
| Change since IPO | -96.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6LP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -2.2% | 2.5% |
| 1Y | -31.1% | -25.2% | 6.0% |
Return vs Industry: 6LP underperformed the German Biotechs industry which returned -21.2% over the past year.
Return vs Market: 6LP underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| 6LP volatility | |
|---|---|
| 6LP Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6LP's share price has been volatile over the past 3 months.
Volatility Over Time: 6LP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Randy Schatzman | www.boltbio.com |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
Bolt Biotherapeutics, Inc. Fundamentals Summary
| 6LP fundamental statistics | |
|---|---|
| Market cap | €39.64m |
| Earnings (TTM) | -€64.23m |
| Revenue (TTM) | €7.31m |
6.1x
P/S Ratio-0.7x
P/E RatioIs 6LP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6LP income statement (TTM) | |
|---|---|
| Revenue | US$7.88m |
| Cost of Revenue | US$61.54m |
| Gross Profit | -US$53.67m |
| Other Expenses | US$15.53m |
| Earnings | -US$69.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | -681.39% |
| Net Profit Margin | -878.58% |
| Debt/Equity Ratio | 0% |
How did 6LP perform over the long term?
See historical performance and comparison